M. Trevethick

发表

Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions

M. Trevethick, S. Mantell, E. Stuart, 2008, British journal of pharmacology.

Ligand binding assays at equilibrium: validation and interpretation

M. Trevethick, E. Hulme, 2010, British journal of pharmacology.

The discovery of long acting β2-adrenoreceptor agonists

Alan Daniel Brown, Mark E. Bunnage, M. Bunnage, 2007 .

Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD.

M. Bunnage, David A. Price, M. Trevethick, 2011, Bioorganic & medicinal chemistry letters.

Optimized glucuronidation of dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD

M. Bunnage, David A. Price, M. Trevethick, 2011 .

The In-Vitro Pharmacology Of PF-4348235 At Recombinant Receptors - A Novel Inhaled Dual Antimuscarinic/Beta2 Adrenoceptor Agonist

M. Trevethick, E. Stuart, M. Yeadon, 2011, ATS 2011.

A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors.

M. Trevethick, S. Summerhill, C. Perros-Huguet, 2008, Journal of pharmacological and toxicological methods.

Molecular hybridization yields triazole bronchodilators for the treatment of COPD.

M. Trevethick, E. Stuart, P. Glossop, 2015, Bioorganic & medicinal chemistry letters.

Design and synthesis of a fluorescent muscarinic antagonist.

M. Trevethick, L. Jones, S. Sreckovic, 2008, Bioorganic & medicinal chemistry letters.

The role of protease‐activated receptors PAR‐1 and PAR‐2 in the repair of 16HBE 14o− epithelial cell monolayers in vitro

M. Trevethick, J. Shute, C. Berger, 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.

D. Walker, M. Trevethick, E. Stuart, 2009, Bioorganic & medicinal chemistry letters.

UK-500,001, a potent selective inhibitor of phosphodiesterase type 4 (PDE4) designed for inhaled delivery, inhibits TNF-a, MIP-1b and LTB4 released from native blood cells.

M. Trevethick, A. Barnard, M. Yeadon, 2007 .

Inhaled muscarinic antagonists for COPD--does an anti-inflammatory mechanism really play a role?

M. Trevethick, M. Yeadon, Matthew Strawbridge, 2009, Current opinion in pharmacology.

The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor.

M. Trevethick, S. Patel, S. Summerhill, 2011, Pulmonary pharmacology & therapeutics.

Is uridine a treatment for asthma?

M. Trevethick, 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDS and Cox 2 inhibitors

M. Trevethick, C. Grossman, P. Birch, 1995, Inflammation Research.

Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease.

Peter G. Dodd, D. Walker, M. Trevethick, 2008, Bioorganic & medicinal chemistry letters.

Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.

M. Bunnage, David A. Price, A. Wood, 2011, Journal of medicinal chemistry.

Effect of methylprednisolone on the ulceration, matrix metalloproteinase distribution and eicosanoid production in a model of colitis in the rabbit

M. Trevethick, R. Hembry, P. Boulos, 1997, International journal of experimental pathology.

The kappa opioid receptor is associated with the perception of visceral pain

M. Trevethick, D. Black, 1998, Gut.

Effects of isolation and culture on prostaglandin synthesis by porcine aortic endothelial and smooth muscle cells

J. Salmon, S. Moncada, M. Trevethick, 1982, Journal of cellular physiology.

Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.

M. Bunnage, David A. Price, A. Brown, 2010, Journal of medicinal chemistry.

Design and application of locally delivered agonists of the adenosine A2A receptor

M. Trevethick, S. Mantell, Rhys Jones, 2010, Expert review of clinical pharmacology.

IDENTIFICATION OF A HISTAMINE H4 RECEPTOR ON HUMAN EOSINOPHILS—ROLE IN EOSINOPHIL CHEMOTAXIS

M. Trevethick, M. Fidock, S. Trim, 2002, Journal of receptor and signal transduction research.

PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.

M. Trevethick, K. H. Banner, Katharine H Banner, 2004, Trends in pharmacological sciences.

Suppression of inflammatory and immune responses by the A2A adenosine receptor: an introduction

T. Palmer, M. Trevethick, 2008, British journal of pharmacology.

The discovery of adamantyl-derived, inhaled, long acting beta(2)-adrenoreceptor agonists.

Mark E Bunnage, M. Bunnage, David A. Price, 2008, Bioorganic & medicinal chemistry letters.

The potential role of spinal cord cyclooxygenase-2 in the development of Freund's complete adjuvant-induced changes in hyperalgesia and allodynia

M. Trevethick, A. Wheeldon, M. Trevethick, 1997, Neuroscience.

Acute indomethacin-induced jejunal injury in the rat: early morphological and biochemical changes.

R. Pounder, A. Dhillon, M. Trevethick, 1994, Gastroenterology.

Highly potent and selective zwitterionic agonists of the δ-opioid receptor. Part 1

M. Trevethick, Alan S. Jessiman, Carly L. Nichols, 2006 .

Ligand binding assays at equilibrium: validation and interpretation

M. Trevethick, E. Hulme, 2010, British journal of pharmacology.

THE β3‐ADRENOCEPTOR AGONIST CL316243 PREVENTS INDOMETHACIN‐INDUCED JEJUNAL ULCERATION IN THE RAT BY REVERSING EARLY VILLOUS SHORTENING

R. Pounder, A. Dhillon, M. Trevethick, 1996 .